ADL 5859

Drug Profile

ADL 5859

Alternative Names: ADL-5859; PF-04856880; PF-4856880

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adolor Corporation
  • Developer Adolor Corporation; Pfizer
  • Class Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid delta receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Dental pain; Inflammatory pain; Neuropathic pain

Most Recent Events

  • 18 Jun 2010 Efficacy and adverse events data from a phase IIa trial in Inflammatory pain (osteoarthritis of knee) released by (Adolor Corporation)
  • 30 Oct 2009 Adolor and Pfizer initiate a phase IIa proof-of-concept trial for patients with osteoarthritis in the US
  • 15 Dec 2007 Phase-II clinical trials in Neuropathic pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top